AZN Astrazeneca plc

  1. Stocks
  2. Healthcare
  3. NYSE: AZN

Price (delayed)

$169.47

Market cap

$262.51B

P/E Ratio

25.26

Dividend/share

$3.18

EPS

$6.71

Enterprise value

$288.87B

?
Relative Growth: Rel. Growth: 94
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: 60
Relative Profitability: Rel. Profitability: 96

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Highlights
AZN's price to earnings (P/E) is 80% lower than its 5-year quarterly average of 125.8 and 7% lower than its last 4 quarters average of 27.2
Astrazeneca's EPS has increased by 34% YoY
AZN's equity is up by 15% year-on-year but it is down by 2.7% since the previous quarter
The quick ratio rose by 6% year-on-year but it has declined by 2.7% since the previous quarter
AZN's debt is up by 15% since the previous quarter and by 7% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.astrazeneca.com/
Peers: PFE BMY MRK JNJ

Key stats

What are the main financial stats of AZN

AZN stock price

How has the Astrazeneca stock price performed over time
Intraday
-1.25%
1 week
-10.88%
1 month
-5.19%
1 year
19.13%
YTD
-7.83%
QTD
-10.63%

Financial performance

How have Astrazeneca's revenue and profit performed over time
Revenue
$60.44B
Gross profit
$49.37B
Operating income
$14.32B
Net income
$10.39B
Gross margin
81.7%
Net margin
17.2%
AZN's operating income is up by 36% year-on-year and by 4.2% since the previous quarter
AZN's net income is up by 34% year-on-year
The operating margin has grown by 23% YoY
AZN's net margin is up by 22% year-on-year

Price vs fundamentals

How does AZN's price correlate with its fundamentals

Growth

What is Astrazeneca's growth rate over time

Valuation

What is Astrazeneca stock price valuation
AZN P/E details
P/E
25.26
P/B
5.55
P/S
4.34
EV/EBIT
19.72
EV/EBITDA
14.12
EV/Sales
4.78
AZN's price to earnings (P/E) is 80% lower than its 5-year quarterly average of 125.8 and 7% lower than its last 4 quarters average of 27.2
Astrazeneca's EPS has increased by 34% YoY
AZN's equity is up by 15% year-on-year but it is down by 2.7% since the previous quarter
Astrazeneca's revenue has increased by 10% YoY and by 2.9% QoQ
The stock's price to sales (P/S) is 6% less than its 5-year quarterly average of 4.6 and 3.6% less than its last 4 quarters average of 4.5

Efficiency

How efficient is Astrazeneca business performance
Astrazeneca's return on invested capital has increased by 24% YoY
The return on assets is up by 23% year-on-year
Astrazeneca's return on sales has increased by 22% YoY
The company's return on equity rose by 16% YoY

Dividends

What is AZN's dividend history
Dividend details
DPS
$3.18
Dividend yield
1.88%
Payout ratio
47.4%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Astrazeneca financials performed over time
The company's total assets is 71% higher than its total liabilities
The company's total assets rose by 7% YoY
The quick ratio rose by 6% year-on-year but it has declined by 2.7% since the previous quarter
AZN's debt is 28% smaller than its equity
AZN's debt to equity is up by 18% since the previous quarter but it is down by 6% year-on-year
AZN's equity is up by 15% year-on-year but it is down by 2.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.